Alternative complement pathway assessment in patients with atypical HUS.
about
Atypical hemolytic uremic syndromeRecessive mutations in DGKE cause atypical hemolytic-uremic syndromeCurrent state of renal transplant immunosuppression: Present and futureCurrent Understanding of the Role of Complement in IgA NephropathyCurrent treatment of atypical hemolytic uremic syndromeComplement System Part II: Role in ImmunityFactor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein.Thrombotic microangiopathy and associated renal disorders.Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies.Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndromeUse of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects.Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome.Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses.[Pathophysiology of atypical hemolytic uremic syndrome. Ten years of progress, from laboratory to patient].Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?Dynamics of complement activation in aHUS and how to monitor eculizumab therapyAnalysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation.Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case reportMapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS).Post-bone marrow transplant thrombotic microangiopathy.The alternative complement pathway regulates pathological angiogenesis in the retinaCurrent evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.Complement System Part I - Molecular Mechanisms of Activation and Regulation.Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosisComplement involvement in kidney diseases: From physiopathology to therapeutical targetingA Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor HInsights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.An Inhibitor of the Alternative Pathway of Complement in Saliva of New World Anopheline Mosquitoes.The complement cascade and renal disease.American Society of Nephrology clinical pathological conference.Disease-causing mutations in genes of the complement system.Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.Making sense of the spectrum of glomerular disease associated with complement dysregulation.Heparin/heparan sulphate interactions with complement--a possible target for reduction of renal function loss?
P2860
Q21202864-5D7CFF67-41B3-4770-B574-1A1D61990AB2Q24337607-44061303-6428-4338-93F9-0A3E543E2506Q26829789-068CF802-CD03-41CB-B44A-91DD70D865D6Q26852163-FF5DD7A5-4365-4E10-881F-9158A69D6CE7Q27003211-3FEA5C1A-757A-492B-8CE1-F44067F57C3FQ28263460-55F573EC-2773-466F-BA57-6DF259FBA7ADQ33399052-420255DC-6DDA-424C-A0F8-DEDDB1116131Q33399198-45AD16B3-2166-4E07-9070-E667273FC9E3Q33400705-054487B4-0F86-40E5-9B56-2DB22FB9A0C8Q33402372-5F0CD9C5-AAAB-4775-9A91-A385194CEEBEQ33402784-1B3ABC58-B6B0-4A1D-AB88-6AD6589360B1Q33402827-57483108-25C5-49C2-A520-4831FD38ACC8Q33403607-A304E70B-48C4-4C05-A27D-CCAE6E47E143Q33404888-F3EEA2DB-58D5-4CD9-8B7E-B2B1040BE48AQ33405246-8BC32AF5-66D0-4E05-AD77-5C70B49CEDD0Q33405522-2EC40C8E-5403-48A4-9515-6139C598D0F4Q33409198-F3D712F6-28F4-4EC8-B1C9-1C86C7BBCFACQ33413660-9A03575C-752D-41F6-8ABE-87D72FACA82AQ33414109-01F74ADF-6FB0-43A4-B156-6486916B7D70Q33416519-62D2B4D1-69E8-4D57-8615-012C9105D338Q33417165-05CADF93-FDDD-40AE-B553-3BA6CD726538Q33417655-DDBACCC0-AEB6-45E4-898A-1FD62795CAEBQ33419905-573BED90-996A-4AAC-8D56-85F484BB52AAQ33424946-895FDE5D-464B-4FE7-9E11-962976ABD305Q33426147-44F4A474-F168-4B40-8523-AE3B3C2892C1Q33430697-144A796C-4432-4069-9022-5B518D4D0682Q33775122-7577BB36-56D1-49FA-943F-6503A52E5113Q33783126-4CF74EEF-1F1D-4155-8699-417231325359Q34481071-BC6B9593-6964-416E-BA5A-4516BED985EBQ34651178-FDB60ED7-985C-4D98-8A47-9E8EBC842154Q35567841-1227BD98-0177-47DF-90F8-327CB725904CQ35809292-95859940-58E2-4DC7-984A-FE94F48A0294Q36778860-A85D1866-FCB9-4943-92A1-2C54879187F6Q37185654-FCDFA866-DE32-4D8A-99C4-01AB963AC696Q37502706-0013AA0F-A0D6-45FE-96DA-099D6B461F9CQ37682273-D320502B-D5DE-46C0-A956-902240A6B899Q37888153-433B3A1D-AF9D-4290-AF72-15ED6759AB0EQ38048606-C77A2B9D-AE0F-4403-81E0-57E89BA79374Q38121480-153211EF-335F-4EFF-96F6-108BFB4035FCQ38123661-AC4C7B2F-CEDC-4811-80CA-38D4E19172B8
P2860
Alternative complement pathway assessment in patients with atypical HUS.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Alternative complement pathway assessment in patients with atypical HUS.
@ast
Alternative complement pathway assessment in patients with atypical HUS.
@en
type
label
Alternative complement pathway assessment in patients with atypical HUS.
@ast
Alternative complement pathway assessment in patients with atypical HUS.
@en
prefLabel
Alternative complement pathway assessment in patients with atypical HUS.
@ast
Alternative complement pathway assessment in patients with atypical HUS.
@en
P2093
P50
P1476
Alternative complement pathway assessment in patients with atypical HUS.
@en
P2093
Chantal Loirat
Lise Halbwachs-Mecarelli
Marie-Agnes Dragon-Durey
Veronique Fremeaux-Bacchi
P356
10.1016/J.JIM.2010.12.020
P50
P577
2011-01-06T00:00:00Z